Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas
| Autor: | Lucile Andrac, Colette Charpin, C. Bouvier, Bénédicte Devictor, Claude Allasia, Stéphane Garcia, Lavaut Mn |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
CD31 Cancer Research Pathology medicine.medical_specialty Cathepsin D Breast Neoplasms Biology Gene product Automation Antigen Biomarkers Tumor Image Processing Computer-Assisted medicine Humans Tissue Distribution ATP Binding Cassette Transporter Subfamily B Member 1 Lymph node Aged Frozen section procedure Immunoperoxidase Middle Aged Immunohistochemistry Molecular biology medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 Receptors Estrogen Oncology Receptors Progesterone Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Expression of the bcl-2 gene was investigated in 218 human breast carcinomas by immunohistochemical analysis. Immunodetections were assessed using (1) frozen sections, (2) documented commercially available monoclonal antibody (bcl-2/124, Dako), (3) automation of immunoperoxidase technique (Ventana) and (4) quantitative evaluation of results by image analysis (SAMBA) and statistical analysis of quantitative data (BMDP software). Bcl-2 protein expression was correlated with current prognostic indicators and with molecular markers detected by the same procedure as for Bcl-2. It was shown that Bcl-2 expression is not related to patients' age, tumour size and type or lymph node status, but an inverse relationship was observed between Bcl-2 and tumour grade (P < 0.0001). An inverse relationship was also observed between Bcl-2 expression and p53 (P < 0.0001), Ki67/MIB1 antigen- (P = 0.0012), and P-gp- (P = 0.002) positive immunoreactions. In contrast, anti-Bcl-2 positive reaction was significantly associated with ER-positive (P < 0.001) and with ER/PR-positive or ER/PR/pS2-positive immunoreactions (P < or = 0.005). Bcl-2 expression was independent of CD31 and cathepsin D expression. Thus, Bcl-2 protein, thought to be antiapoptotic, exhibits parodoxical expression in human breast carcinomas. It is strongly detected in low-grade tumours (well-differentiated) with low (MIB1) growth fraction, but is independent of the tumour progression (size, node status, CD31, and cathepsin D). Bcl-2 acting on apoptosis is related to p53 gene abnormalities in breast carcinomas. Bcl-2 protein expression may also be involved in response to endocrine therapy (associated to ER/PR/pS2 positive immunoreactions) and probably with chemoresistance mechanisms (inverse relationship with P-gp). Images Figure 1 Figure 2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|